| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 08/11/2023 | 403.6% | Capital One | → $7 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/25/2023 | 392.81% | EF Hutton | → $6.85 | Assumes | → Buy |
| 05/16/2023 | 475.54% | Oppenheimer | → $8 | Reinstates | Outperform → Outperform |
| 05/15/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/15/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 03/09/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 03/09/2023 | 331.65% | Cantor Fitzgerald | → $6 | Reiterates | → Overweight |
| 03/09/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | → Outperform |
| 02/27/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/21/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/17/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/16/2023 | 392.81% | EF Hutton | $4 → $6.85 | Maintains | Buy |
| 02/07/2023 | 331.65% | Cantor Fitzgerald | $10 → $6 | Reiterates | → Overweight |
| 01/11/2023 | 115.83% | Credit Suisse | $7 → $3 | Maintains | Outperform |
| 01/11/2023 | 187.77% | EF Hutton | → $4 | Maintains | Buy |
| 11/14/2022 | 475.54% | Oppenheimer | $21 → $8 | Maintains | Outperform |
| 11/01/2022 | 187.77% | EF Hutton | → $4 | Initiates Coverage On | → Buy |
| 07/13/2022 | 475.54% | Credit Suisse | $9 → $8 | Maintains | Outperform |
| 05/13/2022 | 547.48% | Credit Suisse | $10 → $9 | Maintains | Outperform |
| 02/28/2022 | 619.42% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 02/25/2022 | 619.42% | Credit Suisse | $15 → $10 | Maintains | Outperform |
| 11/08/2021 | 979.14% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 10/21/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 10/20/2021 | 1266.91% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 10/13/2021 | 1410.79% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
What is the target price for Jasper Therapeutics (JSPR)?
The latest price target for Jasper Therapeutics (NASDAQ: JSPR) was reported by Credit Suisse on August 14, 2023. The analyst firm set a price target for $4.00 expecting JSPR to rise to within 12 months (a possible 187.77% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ: JSPR) was provided by Credit Suisse, and Jasper Therapeutics reiterated their outperform rating.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Jasper Therapeutics (JSPR) is trading at is $1.39, which is within the analyst's predicted range.